Related Experiment Video
Updated: Jul 1, 2025

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Duvelisib: A comprehensive profile.
Haya I Aljohar1, Ebtehal Al-Abdullah1, Nourah Z Alzoman1
1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Duvelisib (DUV) is a novel dual phosphoinositide-3-kinase (PI3K) inhibitor approved for treating certain lymphomas. This review covers its chemical properties, preparation, and therapeutic applications in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Background:
- Duvelisib (DUV) is a novel small molecule drug.
- It exhibits dual phosphoinositide-3-kinase (PI3K) inhibitory activity.
- DUV is approved for adult patients with small lymphocytic lymphoma (SLL) and relapsed or refractory chronic lymphocytic leukemia (CLL).
Conclusions:
- Duvelisib (DUV) is an important therapeutic agent for specific B-cell malignancies.
- This review consolidates critical information on Duvelisib's properties and applications.
- Further understanding of Duvelisib supports its clinical use in oncology.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
Related Concept Videos
Preclinical Development: Overview
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...